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killed 18 hr after administration of the labeled drug. Analysis of the various brain areas showed that 
with the exception of the cerebellum, residual E3H]reserpine concentrations were markedly iowered 
in all brain areas (Table 2), indicating that mutual ~eserpine-tetrabe~~ne sites are w~d~pread in the 
brain. 
The other way of establishing the specificity of reserpine binding was by taking advantage of the 
observation that specific reserpine binding sites are readily saturated and that pretreatment with 
unlabeled reserpine well in advance of the labeled drug greatly reduces the persistent binding of the 
latter.’ Accordingly, rats were given unlabeled reserpine (0.5 mgjkg, i.m.) 6 hr before [jH]reserpine 
and were killed 18 hr after administration of the labeled compound. As was the case with tetra- 
benazine pretreatment, concentrations of [3H]reserpine were markedly lowered in all areas except 
the cerebellum (Table 2). 
These findings suggest that specific reserpine binding sites are widespread in the brain and that they 
are not well correlated with the ~atomic~ distribution of any single brain monoamine although 
the degree of reserpine binding in peripheral organs seems to be correlated with the degree of adrener- 
gic innervation.’ The present results suggest further that specific and persistent reserpine binding in 
cortex, which has a low content of any of the endogenous monoamines, may reveal the presence of 
m~noaminer~ic systems not associated with large amine storage pools. Other evidence that there 
may exist such systems has been presented by Snyder and Coyle* who showed that the cerebral cortex, 
a norepinephrine-poor area, takes up norepinephrine in vitro almost as well as the norepinep~rine* 
rich hypothalamus. If such hidden systems should exist, it would follow that the subcellular site of 
reserpine binding in brain may not necessarily be limited only to amine storage granules within 
monoamine&c neurones or, alternatively, that in some brain regions such granules have a low 
monoamine content. 
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Inhibition of cholesterol side-chain cleavage by azachoIesterols* 
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INHIBZTORS of cholesterol side-chain cleavage are of interest because of their possible diagnostic and 
therapeutic utility in diseases associated with hyperfunctioning adrenal glands.’ One such inhibitor, 
aminoglutethimide (I), is known to block the conversion of cholesterol (III) to 20=-hydroxycholesterol 
* This study was supported by Grants HE-11274 from the National Institutes of Health and 
PRA-18 from the American Cancer Society. 
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FIG. 1. Proposed intermediates in cholesterol side-chain cleavage. 
(IV)*s3 and thereby cause a reduction in the formation of all hormonal steroids, includingcortisol and 
aldosterone.4*5 Our previous studies6 with azacholesterols suggested that some of these isosteres of 
cholesterol would be effective competitive inhibitors of the side-chain cleavage reaction. Investigation 
of several azacholesterols revealed that 22-azacholesterol (II) represents the most potent inhibitor of 
cholesterol side-chain cleavage reported to date. 
Recent studies on the side-chain cleavage reaction in endocrine tissues showed that the sequence of 
events is more complicated than originally presumed. The initial proposals suggested that 20a- 
hydroxylation was the first and rate-limiting step in pregnenolone (VIII) and subsequent steroid 
biosynthesis.7*8 More recent studies by Burstein and Gut, 9*10 however, revealed that 22 (R)-hydroxy- 
cholesterol (V) is the more important monohydroxycholesterol intermediate. Moreover, their kinetic 
data supported the assumption that a more significant pathway may be via the direct formation of 
20a,22(R)-dihydroxycholesterol (VII). Additional support for V and VII as key intermediates was pro- 
vided by the isolation of these sterols from bovine adrenal glands. I1 In addition, Van Lier and SmithI 
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presented evidence to suggest that the initial intermediate may be a 20a-hydroperoxide of cholesterol 
(VI). They found that VI could readily undergo enzymic conversion to the diol VII. Obviously many 
questions remain unanswered, but a selective inhibitor of any one of these enzymic reactions may 
prove a valuable tool to aid in the elucidation of the mechanism for the cleavage reaction. 
Assays for cholesterol side-chain cleavage activity were performed according to the method of 
Doering. I3 An acetone powder preparation of the mitochondrial fraction of bovine adrenal cortex 
was used as the enzyme source. The powder was reconstituted in 0.01 M phosphate buffer (pH 7.4) 
to give a protein concentration of 5-8 mg/ml as determined by the method of Lowry et ~1.‘~ Use of 
cholesterol-7a-3H,26-‘4C as the substrate allowed volatilization of one of the cleavage products as 
isocaproic acid-W. The enzymic activity was readily calculated from a change in the isotope ratios. 
The inhibitory activity of the test compounds was determined at a final concentration of 0.1 mM 
or less. In all determinations, controls were run in the absence of inhibitor and the per cent inhibition 
was the average of at least two experiments. Table 1 compares the inhibitory activity of three aza- 
cholesterols and two diazacholesterols with that for aminoglutethimide. Pregnenolone was also 
included, since it is known to act as a feedback inhibitor of the cleavage reaction.15 
TABLE 1. INHIBITORY ACTIVITY OF AZA ANALOGS OF 






20-Azacholesterol 100 79.1 
10 60.3 
1 4.2 




25-Azacholesterol 100 35.5 
10 0 
20,25-Diazacholesterol 100 36.4 
22,25-Diazacholesterol 100 69.7 
Aminoglutethimide 100 40.2 
Pregnenolone 100 29.4 
* In all experiments a substrate concentration of 3.3 x 10egM 
was used. The incubations were carried out at 37.5” with 0.5 mg 
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FIO. 2. Competitive inhibition of cholesterol side-chain cleavage by 22-azacholesterol (K1 = 2.2 PM). 
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22-Azacholesterol was the most potent inhibitor studied (& = 2.2 pM, Fig. 2) and has several 
times the activity of aminoglutethimide. The nature of the inhibition was determined by the method of 
Dixon’e and was shown to be competitive with substrate (Fig. 2). Interestingly, 22-azacholesterol was 
slightly more inhibitory than 20-azacholesterol and agrees with the current view that 22 (R)-hydroxyl- 
ation rather than 20a-hydroxylation is the more significant step in the cleavage reaction. 
Previous studies with the azacholesterols showed that 2%azacholesterol and the two diaza analogs 
are potent inhibitors of cholesterol biosynthesis and cause a reduction in serum cholesterol levels of 
hypercholesterolemic rats at very low doses. 6*17*18 By contrast, 20- and 22-azacholesterol failed to 
cause any hypochoiesterolemic effect at high doses. Thus the ability of 20- and 22-azacholesterol to 
inhibit the cleavage reaction appears to be somewhat specific and this specificity is decreased by 
replacement of C-25 with an N atom. 
20,25-Diazacholesterol (Ornitrol) is currently employed as a chemosterilant in the control of pest 
pigeon populations.‘* Ingestion of this compound by pigeons causes inhibition of egg production and 
temporary sterility. Although the exact mode of action of this agent in pigeons is unknown, the above 
studies suggest that inhibition of cholesterol side-chain cleavage and an accompanying decrease in 
steroid hormone production may play a role in the antifertility action of the drug. 
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